RSI Oversold Stocks
VALN is flagged as RSI oversold, meaning recent selling pressure has pushed momentum to extreme levels that may lead to a short-term rebound.
VALNEVA SE - ADR (VALN) Stock Price & Overview
NASDAQ:VALN • US92025Y1038
Current stock price
6.1 USD
-0.17 (-2.71%)
At close:
6.1 USD
0 (0%)
After Hours:
The current stock price of VALN is 6.1 USD. Today VALN is down by -2.71%. In the past month the price decreased by -45.09%. In the past year, price increased by 2.03%.
VALN Key Statistics
52-Week Range5.4289 - 12.25
Current VALN stock price positioned within its 52-week range.
1-Month Range6.04 - 11.77
Current VALN stock price positioned within its 1-month range.
- Market Cap
- 529.947M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.54
- Dividend Yield
- N/A
VALN Stock Performance
Today
-2.71%
1 Week
-3.48%
1 Month
-45.09%
3 Months
-31.88%
Longer-term
6 Months -46.44%
1 Year +2.03%
2 Years -18.12%
3 Years -35.42%
5 Years N/A
10 Years N/A
VALN Stock Chart
VALN Stock Screens
VALN currently appears in the following ChartMill screener lists.
VALN Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to VALN. When comparing the yearly performance of all stocks, VALN is a bad performer in the overall market: 83.05% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
VALN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VALN. VALN has a bad profitability rating. Also its financial health evaluation is rather negative.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
VALN Earnings
On March 16, 2026 VALN reported an EPS of -0.54 and a revenue of 29.44M. The company missed EPS expectations (-90.69% surprise) and missed revenue expectations (-26.86% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateMar 16, 2026
PeriodQ3 / 2025
EPS Reported-€0.54
Revenue Reported29.438M
EPS Surprise -90.69%
Revenue Surprise -26.86%
VALN Forecast & Estimates
11 analysts have analysed VALN and the average price target is 17.37 USD. This implies a price increase of 184.82% is expected in the next year compared to the current price of 6.1.
For the next year, analysts expect an EPS growth of -619.02% and a revenue growth -7.65% for VALN
Analysts
Analysts81.82
Price Target17.37 (184.75%)
EPS Next Y-619.02%
Revenue Next Year-7.65%
VALN Groups
Sector & Classification
VALN Financial Highlights
Over the last trailing twelve months VALN reported a non-GAAP Earnings per Share(EPS) of -1.54. The EPS decreased by -1180% compared to the year before.
Income Statements
Revenue(TTM)274.97M
Net Income(TTM)-120.41M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.86% | ||
| ROE | -80.02% | ||
| Debt/Equity | 0.89 |
Chartmill High Growth Momentum
EPS Q2Q%-271.43%
Sales Q2Q%-35.76%
EPS 1Y (TTM)-1180%
Revenue 1Y (TTM)19.89%
VALN Ownership
Ownership
Inst Owners24.55%
Shares86.88M
Float76.75M
Ins Owners0.21%
Short Float %0.23%
Short Ratio3.17
VALN Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VALN
Company Profile
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 695 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Company Info
IPO: 2007-06-28
VALNEVA SE - ADR
6, Rue Alain Bombard
Saint-Herblain PAYS DE LA LOIRE FR
CEO: Thomas Lingelbach
Employees: 695
Phone: 33228073710
VALNEVA SE - ADR / VALN FAQ
What does VALN do?
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 695 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
What is the current price of VALN stock?
The current stock price of VALN is 6.1 USD. The price decreased by -2.71% in the last trading session.
What is the dividend status of VALNEVA SE - ADR?
VALN does not pay a dividend.
What is the ChartMill technical and fundamental rating of VALN stock?
VALN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for VALNEVA SE - ADR?
VALNEVA SE - ADR (VALN) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for VALNEVA SE - ADR?
The Revenue of VALNEVA SE - ADR (VALN) is expected to decline by -7.65% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.